Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events

Table of contents

Date: 07/04/2021
Location: Virtual meeting

Event summary

EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 7 April 2021.


  • Emer Cooke (Executive Director)
  • Sabine Straus (Chair of PRAC
  • Peter Arlett (Head of Data Analytics and Methods Task Force) 

The press briefing will be moderated by Ms Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.

How useful was this page?

Add your rating
15 ratings
4 ratings
1 rating
3 ratings
15 ratings